Can a Glucose Monitor Detect Insulin Resistance?

Woolf Software
cgm insulin-resistance biomarkers metabolic-health data-analysis
A lab instrument with two glass columns, one lit by a rising amber ribbon of light, the other dark and capped, above a small disc of living tissue.

A continuous glucose monitor cannot, on its own, detect insulin resistance. The reason is structural rather than technical: glucose is the controlled variable in a feedback loop, and insulin is the control signal. Early insulin resistance is compensated, meaning the pancreas raises insulin output while glucose stays close to normal for years. A CGM worn during that period shows a mostly unremarkable trace.

What the sensor needs alongside it is at least one measurement of the input to the loop. In practice that means a fasting insulin drawn with a simultaneous glucose, and ideally insulin sampled during a standardized challenge. With that pairing in hand, CGM data becomes genuinely informative. It tells you how your compensated system behaves under real meals across two weeks, at 288 samples per day.

This page is about measurement and interpretation. Diagnosis, and any decision about what to do next, belongs with a clinician.

What the sensor measures

Before interpreting any trace, it helps to be clear about what the hardware is reporting and how faithfully it reports it. Dexcom G7, Libre 3, and Stelo all measure glucose in interstitial fluid using a glucose-oxidase electrode rather than glucose in blood. Interstitial glucose lags plasma by roughly 5 to 15 minutes, and that lag widens when glucose is changing quickly. On a steep rise after a meal, the sensor reading trails the true value, so the reported peak arrives later and looks flatter than the plasma peak. The device also applies smoothing and, on some systems, a physiologic-plausibility filter. Both blunt sharp excursions further.

Accuracy is conventionally reported as MARD, the mean absolute relative difference between the sensor and a reference laboratory assay. Current consumer sensors land near 8 to 10 percent overall, and perform worse in the hypoglycemic range and during the first 12 to 24 hours of wear. For the purpose of interpreting insulin resistance, the practical implication is that absolute values carry an error bar of roughly ±10 mg/dL in the normal range. Comparisons made within a single sensor are much tighter, such as meal A versus meal B on the same sensor on the same day. Designing your analysis around within-sensor contrasts is therefore the way to get the most out of the data.

Several failure modes are worth understanding before you analyze anything, because each one produces artifacts that look like real physiology:

  • Compression lows. Lying on the sensor reduces local perfusion and produces a smooth 40 to 60 mg/dL overnight dip that recovers within minutes of moving. Exclude nocturnal nadirs that recover in under 20 minutes with no matching symptom or event.
  • Day 1 drift. Drop the first 12 hours of every sensor session.
  • Sensor-to-sensor offset. Two sensors worn at the same time can differ systematically by 10 to 15 mg/dL. Do not stitch fasting-glucose trends across sessions without anchoring each session to a lab or fingerstick value.
  • Acetaminophen interference on older glucose-oxidase chemistries. G7 and Libre 3 are largely immune at normal doses, but check your device’s label.

The measurements that make a CGM interpretable

Since the sensor cannot see insulin, a small set of laboratory measurements does the work of characterizing the input side of the loop. The minimum useful panel, drawn fasting on the same morning, is glucose, insulin, triglycerides, HDL, and HbA1c. From those values you can compute two indices:

HOMA-IR = (fasting insulin [µU/mL] × fasting glucose [mg/dL]) / 405
TyG     = ln( fasting TG [mg/dL] × fasting glucose [mg/dL] / 2 )

HOMA-IR is a hepatic-dominant index computed from a single time point, so it inherits the day-to-day variability of a fasting insulin assay, which is substantial. A single value is best treated as a wide interval rather than a number. Insulin immunoassays also differ across laboratories in how much they cross-react with proinsulin, so serial values are only comparable if you keep the same lab and the same platform throughout.

If you want an estimate of peripheral (muscle) sensitivity, the useful step up is a laboratory 75 g oral glucose tolerance test with insulin drawn at 0, 30, 60, and 120 minutes, which yields the Matsuda index:

Matsuda = 10000 / sqrt( G0·I0 · Gmean·Imean )

That single test separates the two common phenotypes a CGM cannot distinguish: normal glucose with high insulin, which is compensated resistance, and normal glucose with normal insulin. Insulin resistance in this compensated state is the metabolic risk state that matters, and it precedes overt dysglycemia by a long margin.1

HbA1c makes a poor standalone screen in this setting. It reports an average weighted toward the last 30 days, and it is distorted by anything that changes red cell lifespan, including iron deficiency, hemolysis, recent blood donation, and some hemoglobin variants. Its limitations as a glycemic index in populations with altered erythrocyte turnover are well documented, and alternative markers such as 1,5-anhydroglucitol and glycated albumin cover shorter windows and different failure modes.2 1,5-anhydroglucitol is particularly interesting here, because it falls when glucose exceeds the renal threshold and therefore behaves as a marker of postprandial excursions over the prior one to two weeks, which is close to what a CGM samples directly.3

A two-week protocol we would run

Bringing the sensor and the labs together calls for a little planning, so here is the protocol we would use.

  1. Wear one sensor continuously for 14 days. Log meals with timestamps to the minute, and photograph portions if you will not weigh them.
  2. On days 3, 7, and 11, run a standardized challenge: the same fixed meal, eaten within the same 10 minutes, after a 10-hour fast, with no exercise in the preceding 12 hours and none for 2 hours afterward. We use 75 g of carbohydrate from a repeatable source. Repeating the same challenge three times gives you an estimate of your own within-person noise, which is the only way to know whether a difference between two foods is real.
  3. Draw the fasting panel (glucose, insulin, TG, HDL, HbA1c) on a morning inside the wear window.
  4. Cross-check the sensor with 2 or 3 fingersticks at stable fasting glucose to estimate the session offset.

Step 2 deserves a word of explanation, because it is the one people tend to skip. Free-living meal responses are confounded by nearly everything around them: the composition of the prior meal, sleep, the previous day’s activity, and time of day. A standardized challenge repeated three times is the closest thing to a controlled experiment you can run on yourself.

Computing the metrics from the export

Once the wear period is over, the analysis begins with parsing the manufacturer’s export, and the two major formats differ enough to matter. Dexcom Clarity exports a CSV with a Timestamp (YYYY-MM-DDThh:mm:ss) column and a Glucose Value (mg/dL) column, using the strings Low and High at the range boundaries. LibreView exports a semicolon- or comma-delimited CSV with a Record Type column in which 0 is automatic scan history and 1 is manual blood glucose. Parse accordingly.

import pandas as pd, numpy as np

df = pd.read_csv("clarity.csv", parse_dates=["Timestamp (YYYY-MM-DDThh:mm:ss)"])
df = df.rename(columns={"Timestamp (YYYY-MM-DDThh:mm:ss)": "t",
                        "Glucose Value (mg/dL)": "g"})
df["g"] = pd.to_numeric(df["g"].replace({"Low": 39, "High": 401}), errors="coerce")
df = df.dropna(subset=["t", "g"]).set_index("t").sort_index()
g = df["g"].resample("5min").mean().interpolate(limit=3)  # do not bridge >15 min gaps

mean_g = g.mean()
cv     = 100 * g.std() / mean_g
tar140 = 100 * (g > 140).mean()
gmi    = 3.31 + 0.02392 * mean_g   # % HbA1c-equivalent, derived in diabetes cohorts

For a challenge meal starting at t0, these are the numbers we look at:

w    = g.loc[t0 : t0 + pd.Timedelta("3h")]
base = g.loc[t0 - pd.Timedelta("30min") : t0].mean()
peak = w.max()
tpk  = (w.idxmax() - t0).total_seconds() / 60
iauc = np.trapz(np.clip(w.values - base, 0, None), dx=5)   # mg/dL·min above baseline
ret  = (w[w.index > w.idxmax()].le(base + 10).idxmax() - t0).total_seconds() / 60

That gives four features, listed here in rough order of how much each one tells you about the underlying loop:

  • Time to return to baseline (ret). A response that is still 20 mg/dL above baseline at 120 minutes is the CGM shadow of a slow OGTT. This is the feature most closely aligned with 2-hour OGTT glucose.
  • Incremental AUC. Less sensitive than peak to the peak-flattening caused by sensor lag.
  • Time to peak (tpk). Later peaks, beyond roughly 60 minutes for a liquid or fast carbohydrate load, suggest sluggish first-phase suppression of hepatic output.
  • Peak height. The feature most affected by sensor smoothing, so use it only for within-sensor comparisons.

One metric to treat with caution is MAGE, which is best avoided unless you commit to a single implementation. The published variants disagree with one another, and values are not comparable across tools.

Beyond these hand-computed features, the research direction here is worth knowing about. CGM-derived features are being developed as predictive biomarkers in their own right, going beyond time-in-range summaries.4 There is also active work on estimating insulin sensitivity from passively collected daily-life signals, combining glucose with wearable activity and sleep data.5 Models trained on routine minimally invasive labs reach useful discrimination for insulin resistance without requiring an insulin assay. They are calibrated to the populations they were trained on, however, and have not been validated as personal tools.6

What the trace can and cannot rule out

With the metrics computed, the question becomes what conclusions they support. A flat, low-variability two-week trace with fast returns to baseline is evidence against substantial dysglycemia. It is weak evidence about insulin sensitivity, because a young pancreas can hold that trace while running two or three times the insulin a sensitive person needs.

The converse case is equally limited. A trace with 2-hour excursions and slow returns is a signal worth taking to a clinician, but it does not constitute a diagnosis. It could reflect impaired secretion rather than resistance, and that distinction changes everything about interpretation. Biomarker panels are used clinically to stratify risk and monitor progression precisely because no single measurement separates these mechanisms.7

Our position follows from all of this: wear the sensor, but also pay for the fasting insulin and the OGTT with insulin. The lab draw costs less than a month of sensors, and it answers the question the sensor cannot.

Questions people also ask

Is a glucose monitor good for insulin resistance? It is good for characterizing your glucose response to specific meals and for tracking change over months. It is not a test for insulin resistance, because it does not measure insulin. Pair it with a fasting insulin and glucose drawn together.

Can a blood glucose test detect insulin resistance? A single fasting glucose will miss compensated insulin resistance entirely, since glucose stays near normal while insulin rises. Fasting glucose plus fasting insulin (HOMA-IR), or an OGTT with insulin sampled at 0/30/60/120 minutes (Matsuda), are the accessible measurements that address it.

What is the best glucose monitor for people who want to study insulin sensitivity? Any 15-day consumer sensor with a clean data export will serve. We prefer Dexcom G7 or Stelo for the 5-minute sampling interval and a Clarity CSV that parses without special cases. Libre 3 is fine, but check whether your export gives you 5-minute or 15-minute records, because 15-minute sampling loses the shape of a fast excursion.

How do I track blood sugar for insulin resistance? Fourteen days of continuous wear, timestamped meal logs, and the same standardized challenge meal repeated three times under matched conditions. Analyze incremental AUC and time to return to baseline rather than peak alone, and discard the first 12 hours of each sensor session.

How long does it take to change? That depends on the mechanism and on what a clinician determines is driving it, which lies outside what a sensor can tell you. What you can do is measure: re-run the same standardized challenge and the same fasting panel at the same lab after 8 to 12 weeks, and compare within-person rather than against population reference ranges.

Woolf Software builds longitudinal molecular profiles of individuals: whole-genome sequencing, RNA sequencing, proteomics, blood biomarkers, and continuous glucose data, integrated into one model of you. Build your profile.

Footnotes

  1. Marijana Matek Sarić, Nataša Lisica Šikić, Tamara Sorić, et al. Insulin Resistance as a Systemic Metabolic Risk State for Cancer: Mechanisms, Biomarkers, and Prevention. International Journal of Molecular Sciences, 2026. https://doi.org/10.3390/ijms27125495 ↩

  2. Uchenna Esther Okpete, Haewon Byeon. Limitations of glycated hemoglobin and emerging biomarkers for diabetes care after bariatric surgery. World Journal of Diabetes, 2025. https://doi.org/10.4239/wjd.v16.i7.107928 ↩

  3. Haiying Xu, Renyin Chen, Xiaoli Hou, et al. The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus. Frontiers in Endocrinology, 2024. https://doi.org/10.3389/fendo.2024.1471577 ↩

  4. Haewon Byeon. Future of diabetic foot risk: Unveiling predictive continuous glucose monitoring biomarkers. World Journal of Diabetes, 2025. https://doi.org/10.4239/wjd.v16.i6.107006 ↩

  5. Mia Jovanova, Victoria Bruegger, Radoslava Švihrová, et al. Digital biomarkers for insulin resistance screening in daily life. 2026. https://doi.org/10.64898/2026.05.20.26353669 ↩

  6. Weihao Gao, Zhuo Deng, Zheng Gong, et al. AI-driven prediction of insulin resistance in non-diabetic populations using minimal invasive tests: comparing models and criteria. Diabetology & Metabolic Syndrome, 2025. https://doi.org/10.1186/s13098-025-01920-4 ↩

  7. Benjamin M Scirica. Use of Biomarkers in Predicting the Onset, Monitoring the Progression, and Risk Stratification for Patients with Type 2 Diabetes Mellitus. Clinical Chemistry, 2017. https://doi.org/10.1373/clinchem.2016.255539 ↩